Amazon's 2024 revenue reached $638 billion, maintaining its rapid growth. A 20-for-1 stock split in 2022 made Amazon shares more accessible at $115 each. ETFs offer a passive investment option in ...
NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost-effectiveness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results